5 Minutes Read

Omicron subvariant BA.5 more virulent and replicates rapidly, study in mice finds

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The genetically modified mice, called K18-hACE2, used in the research express a human receptor that allowed SARS-COV-2 to enter otherwise inaccessible mouse cells, according to PTI.

Scientists have used engineered mice to compare SARS-COV-2 Omicron subvariants and found that the BA.5 strain was more virulent likely due to its ability to rapidly replicate early during infection.

The research, published in the journal Science Advances, addresses a challenge to studying and understanding rapidly evolving variants of concern due to a lack of animal models for running tests that could help explain why variants and subvariants each behave differently in people.

The genetically modified mice, called K18-hACE2, used in the research express a human receptor that allowed SARS-COV-2 to enter otherwise inaccessible mouse cells.

“One of the things we found is that the strain that causes more pathology, BA.5, replicates much faster early on during infection,” said Avery August, a professor in the College of Veterinary Medicine (CVM) at Cornell University in the US.

“By doing that, the virus generates a really strong immune response, which then leads to increased pathology and symptoms compared to subvariants that don’t replicate as fast,” August said.

Prior to this study, there were no small animal models to study the new SARS-CoV-2 Omicron variants of concern, because no animals got sick with other variants, the researchers said.

“Our study allows us to use relatively older K18-hACE2 mice as a disease model to understand how the virus becomes pathogenic, and to test whether and how vaccines and antivirals work for the new Omicron sub-variants,” said Hector Aguilar-Carreno, a professor of virology at CVM.

Early Omicron BA.1 and BA.2 subvariants also replicated and spread in the K-18 mice, but they caused minimal illness and death.

On the other hand, BA.5-infected mice exhibited significant weight loss, high pathology in lungs, high levels of inflammatory cells and cytokines, signaling proteins that are associated with inflammation.

While some 3-month old mice survived, all 5 to 8 month-old BA.5-infected mice died.

The animal model makes it possible for researchers to begin to tease apart components of the immune system that could be focused on or blocked to potentially lessen or eliminate disease, the researchers said.

Some scientists believe that targeting cytokines with drugs could provide a potential treatment that tempers the immune response and lessens symptoms, they said.

The researchers found many similarities between the mouse model and how these subvariants behave in humans, with BA.5 being more virulent in both. One big difference was that most people who developed illness from BA.5 didn’t die, but in K-18 mice, the subvariant was particularly pathogenic and lethal.

An advantage of the mouse model is that all the mice are identical with the same genetic background. When studying humans, many variables – such as previous conditions, genetics and whether someone has previously been immunised or infected – can affect the pathological outcome of the disease.

Also, the mouse model allowed the researchers to examine disease in the lungs over time.

“With BA.5, we see more pathology early on during the infection compared to mice infected with other strains or the control mice,” August said.

The team also found higher viral loads in the strain that caused more infection. Older mice were more affected by the virus than younger mice as well.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

‘Eris’ or EG.5.1.1: Maharashtra records single case of new COVID-19 Omicron subvariant

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

A new sub-variant of Omicron, EG.5.1.1, has been identified in Maharashtra, with only one recorded case in May.

Maharashtra has recorded its first and only case of the new coronavirus Omicron subvariant named EG.5.1.1 or “Eris.” Officials, however, have not released any information on the individual who contracted the variant or any details on gender, age and travel history.

However, there is no cause for alarm, officials said on Wednesday, as there is only one recorded case from May.

“The variant, EG.5.1.1, was found in May and we have been monitoring it. It is not of any public health importance,” Babita Kamlapurkar, the health surveillance officer for Maharashtra, said.

Is there cause for concern?

The Eris variant is said to be the most dominant in the United States and makes up the largest proportion of new COVID-19 infections, according to the Centers for Disease Control and Prevention.

However, officials believe it’s not as bad as previous subvariants which caused large spikes in cases. COVID-19 hospitalisations are on the rise in the US which reported a 12 percent hike in hospital admissions in a week, coming to about  9,056 as of July 29.

“There are a couple that we’re watching, but we’re not seeing anything like delta or omicron,” Cristin Young, an epidemiologist at Biobot Analytics, the CDC’s wastewater surveillance contractor, said, referencing variants that fueled previous surges.

And mutations in the virus don’t necessarily make it more dangerous.

“Just because we have a new subvariant doesn’t mean that we are destined to have an increase in bad outcomes,” Dowdy said.

How can we be prepared?

In the US, updated coronavirus vaccines that contain one version of the omicron strain called XBB.1.5, are likely to be rolled out before the end of the year. It’s an important change from today’s combination shots, which mix the original coronavirus strain with last year’s most common omicron variants.

However, itt’s not clear exactly when people can start rolling up their sleeves for what officials hope is an annual fall COVID-19 shot.

Maharashtra’s Babita Kamlapurkar also emphasised the importance of maintaining COVID-19-appropriate behaviour, particularly during the months of June, July and August, which historically witness an upswing in case numbers.

“There is no reason to worry. The Centre has also said it has been continuously monitoring the variant and there is no need to worry,” she confirmed.

Kamlapurkar reiterated that regular surveillance of COVID-19 variants remains an ongoing practice.

With agency inputs.

 

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Gennova’s Omicron-specific booster vaccine gets DCGI approval

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The vaccine remains stable at temperatures between 2-8 °C, due to which it does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment pan India. 

India’s Drug Controller General of India (DCGI) has granted approval to Gennova Biopharmaceuticals for its mRNA-based Omicron-specific booster vaccine.

The vaccine, named GEMCOVAC®-OM, is intended for individuals aged 18 years and older as a booster dose. It can be safely administered to individuals who have already received two doses of either Covaxin or Covishield.

The vaccine is administered intradermally using a needle-free device, and it remains stable at temperatures between 2-8 °C, due to which it does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment pan India.

The Department of Biotechnology (DBT) has facilitated establishing the vaccine manufacturing for developingthe platform technology from proof of concept till Phase I clinical trial of the prototype mRNA-based vaccine developed against the Wuhan strain.

Also read: FDA votes for COVID vaccines targeting XBB variants, Pfizer aims for July production

Union Minister Jitendra Singh commended the efforts and said, “I take great pride in DBT fulfilling its mission yet again – enabling technology-driven entrepreneurship through creating this indigenous mRNA-platform technology. We have always supported technology-driven innovation towards the creation of a ‘future-ready’ technology platform in line with the Prime Minister’s vision of Aatmanirbharta.”

He also said, “Infrastructure to deploy vaccine in India, including LMICs, at 2‑8°C exist today & this innovation is tailored for the existing established supply-chain Infrastructure. The vaccine does not need ultra-low temperature conditions for transport and storage.”

Gennova Biopharmaceuticals CEO  Dr. Sanjay Singh, said India has now developed two mRNA vaccines against COVID-19.

“I am proud that my team has worked tirelessly over the last two years to develop the nation’s first mRNA vaccine. This is a team effort & without the guidance of the Subject Expert Committee of CDSCO and the Vaccine Expert Committee of BIRAC monitoring the project, it would not have been possible.”

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID cases in Mumbai and Delhi spike to hit 5-month high, death count stable

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

K Srinath Reddy, Professor at Public Health Foundation of India believes that this is a virus that has now come to stay with us.

The number of daily new COVID-19 cases has shot up to nearly 1,900 on March 25, the highest since October 28 or the highest in five months. In fact the number of cases have been rising steadily since the past 2 weeks. The Prime Minister (PM) held an emergency meeting to check preparedness, while the health ministry has called for a nationwide mock drill in government hospital on April 10 and April 11.

There is also much written about a new virus variant XBB.1.16. How worried should one get, are all these headlines quite unnecessary? Or is this caution legitimate and are people likely to return to a regime of masks and mass testing?

According to Doctor Chandrakant Lahariya, Epidemiologist, Public Policy and Health Systems Expert, “Though cases are rising this is the first time on March 16, World Health Organization (WHO) redesignated Omicron as a previous variant of concern. So till now there have been five variants of concern globally but right now there is no variant of concern currently circulating, all are previous variants of concern.”

Also Read | COVID-19: Mock drills in Delhi today, across India from April 10-11

“We should be prepared for the rise and fall in the cases. When cases rise, it is logical that government take notice, start doing mock drills but for individual citizen it is not a reason to be worried, unless there is a rise in the hospitalization, which doesn’t seem to be the scenario,” he further added.

Dr Lahariya is the Co-Author of ‘Till We WIN: India’s Fight Against COVID -19 Pandemic’ book.

K Srinath Reddy, Professor at the Public Health Foundation of India believes that this is a virus that has now come to stay with us. “Fortunately for us, in its present form, it is not very virulent and therefore, it is likely to be infected possibly even a little more immune-evasive but not cause serious harm at the population level,” he said.

“There will be some people who are individually vulnerable. People who have serious co-morbidities, particularly elderly debilitated people or people who are immunodeficient and they must protect themselves more by taking the precautionary dose if they have not taken and wear masks in crowded areas,” he added.

Also Read | From plane to truck, car, boat & finally on foot, how Covid-19 vaccine reached remotest parts of India

For more details, watch the accompanying video

Catch all the latest updates from the stock market here

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Daily COVID-19 cases significantly rising in India: Health Secretary Rajesh Bhushan

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Providing an update on the current COVID-19 status in India, Bhushan added that the weekly positivity rate has risen from 0.09 percent in February to 1.08 percent now.

Union Health Secretary Rajesh Bhushan on Thursday reported that India is now seeing an average of 966 new COVID-19 cases per day, a significant increase from the 108 cases per day seen in February. Bhushan’s media briefing comes hours after Prime Minister Narendra Modi held a high-level meeting on COVID, the seasonal flu and India’s public health preparedness yesterday.

Providing an update on the current COVID-19 status in India, Bhushan added that the weekly positivity rate has risen from 0.09 percent in February to 1.08 percent now. He reported that there were 1650 cases in Maharashtra, 1093 cases in Gujarat, and 979 cases in Kerala. The positivity rate in Maharashtra is 4.49 percent. Bhushan also noted that the most recent COVID deaths were of co-morbid individuals.

ALSO READ | Health Ministry issues revised guidelines as COVID-19 cases surge

In terms of global numbers, the health secretary noted that there are still over 94,000 new COVID-19 cases being detected every day. The US accounts for 19.2 percent of total global cases, while Russia accounts for 12.6 percent.

Omicron and other COVID-19 variants

He emphasized that the SARS-CoV-2 virus is mutating and changing over time, and the Omicron variant now has over 1,000 variants. Regarding COVID variants, Bhushan said that most of the assigned variants in India are Omicron’s, which have no significant impact on the functional attributes of the virus-like increased transmissibility, disease severity, or immune escape.

He added that over 1,000 Pango lineages of Omicron have been identified, and only a few variants are designated as sub-variants under monitoring or variants of concern based on transmissibility, disease severity, or immune escape.

ALSO READ | PM Modi chairs review meeting for covid situation, calls to enhance genome sequencing

Bhushan stressed that there is no evidence to suggest any increase in hospitalization or mortality due to the XBB.1.16 or XBB.1.5 variants, which are under intense scientific scrutiny but are not a cause of immediate concern. XBB.1.16 had 105 cases found in Maharashtra, 93 in Telangana, 57 in Karnataka, 54 in Gujarat and 19 in Delhi.

Vaccinations, testing and public health preparedness

In terms of vaccination, Bhushan said that over 220.65 crore total doses have been administered in India, with more than 90 percent of individuals over 12 years of age receiving both doses and 27 percent taking a precautionary dose. Bhushan reported that around a lakh COVID-19 tests were conducted in the past 24 hours in India.

He advised elderly and co-morbid individuals to avoid crowded areas and engage in masking, and states were advised to focus on the 5-fold strategy of Test-Track-Treat-Vaccination and COVID-appropriate behaviour. In addition, he advised states to enhance lab surveillance, test all Severe Acute Respiratory Illnesses, and conduct mock drills in both government and private hospitals to check for COVID preparedness.

ALSO READ | ICMR warns against irrational use of antibiotics, steroids for COVID-19 treatment — Check list here

Since the past six months, 2 percent random sampling of all international passengers at airports has been conducted, Bhushan said. He added that there is currently no plan to enhance this sampling.

India is keeping maximum data in the public domain, and other nations will determine how they share data with the World Health Organisation. The nation’s G20 Presidency is not linked to it must respond to the WHO, but the priority is on global health and creating a medical countermeasures platform with digital interventions to improve universal health coverage, he added.

Seasonal flu

Lastly, Bhushan discussed the flu, saying that it is a seasonal disease present globally for decades. He mentioned that vulnerable populations for the flu include pregnant and lactating mothers, children, and the elderly, and that influenza vaccination in many nations is customized based on the type of flu, which is not yet common in India. He also noted that there are isolated cases of Avian influenza and Swine flu in India.

In an interaction with CNBC-TV18, Dr Vaishali Solao, Head – Critical Care, Fortis Hospital said that influenza every year does have a peak of cases and what we are seeing now is also a similar peak. She also emphasized that COVID cases rising is a matter of concern, but not a matter of panic.

Talking about COVID Solao said, “People just need to take more and more precautions and the only way out of this is basically more and more precautions and vaccinations. So it is a matter of concern but not a matter of panic.”

Talking about spread of new variants, Dr Vishal Rao, Member, Karnataka COVID-19 Task Force mentioned that they do not see any reason to hit the panic button. He said, “We will continue to see new variants come up very regularly, we will see new variants come up very commonly, it’s going to be very crucial for us to monitor them to understand which one of them will reach a critical point to create infectivity like delta.”

Watch: Dr Vishal Rao, Member, Karnataka COVID-19 Task Force and Dr Vaishali Solao, Head – Critical Care, Fortis Hospital in interaction with CNBC-TV18.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID-19 update: Omicron, sub-lineages dominant SARS-CoV-2 variants in India

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

During the last four months, more than 1900 Omicron sub-variants have been detected among the samples analysed by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) across the country, Minister of State for Health Bharati Pravin Pawar said in a written reply.

Omicron and its sub-lineages are the dominant SARS-CoV-2 variants in India, the government informed Rajya Sabha on Tuesday.

During the last four months, more than 1900 Omicron sub-variants have been detected among the samples analysed by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) across the country, Minister of State for Health Bharati Pravin Pawar said in a written reply.

Given the emergence of variants of the COVID-19 virus with variable transmissibility and their possible health implications, INSACOG network laboratories conduct whole genome sequencing of samples for the detection of mutant variants of the virus.

Also Read: Key challenges post COVID is good access to health and healthcare services: WEF

In light of the increasing trajectory of COVID-19 cases noted in China, Singapore, Hong Kong, Korea, Thailand and Japan, an additional requirement of pre-departure testing and uploading of negative COVID-19 RT-PCR test reports and self-health declaration form on Air Suvidha portal was made mandatory in the past for travellers coming from or transiting via these countries, Pawar said.

However, based on the declining COVID-19 trajectory in these countries, an updated guideline was issued on February 10, wherein the additional requirements were dropped.

Two per cent of the total passengers in all incoming international flights are required to undergo post-arrival COVID-19 testing, irrespective of the port of departure to monitor positive cases and their variants, the minister said.

Also Read: Carbon dioxide emissions reached a record high in 2022

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID-19 vaccines effective against Omicron sub-variant BF.7, says Health Minister Mansukh Mandaviya

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

No mortality or rise in transmission was reported in the areas where these variants were detected, the ministry had said in a statement.

Union Health Minister Mansukh Mandaviya on Wednesday said that COVID-19 vaccines being used in India are effective against the Omicron sub-variant, BF.7. The virus variant has been found in several of the 200 COVID-positive samples of international air passengers that have so far been genome-sequenced.

More than 15 lakh international air passengers have been screened so far and 200 of them have tested positive for COVID-19, Mandaviya said on the sidelines of a book launch.

“The genome-sequencing of the 200 samples showed that the BF.7 variant was present in several passengers. Our vaccines are effective against this sub-variant,” he said.

Also read: India detects all Omicron sub-variants in country, ‘no rise in mortality or transmission’

The health ministry had, on January 9, said the sentinel-sequencing of 324 COVID-positive samples lifted from the community between December 29 and January 7 had revealed the presence of all the Omicron variants, such as BA.2 and its sub-lineages including BA.2.75, XBB(37), BQ.1 and BQ.1.1(5), among others.

No mortality or rise in transmission was reported in the areas where these variants were detected, the ministry had said in a statement.

The minister released a book titled “Braving A Viral Storm,” which has been authored by Aashish Chandorkar and Suraj Sudhir, at the Constitution Club here on Wednesday.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID pandemic offers health insurers a much broader and long-term opportunity, but will they raise the premiums?

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

COVID-induced pandemic changed the world in more ways than one. As people came in terms with one of the biggest health disasters that the humanity has ever faced, it made them to think if their health insurance was enough to meet unforeseen challenges. With the rapid spread of the latest Omicron subvariant of COVID-19 in …

COVID-induced pandemic changed the world in more ways than one. As people came in terms with one of the biggest health disasters that the humanity has ever faced, it made them to think if their health insurance was enough to meet unforeseen challenges.

With the rapid spread of the latest Omicron subvariant of COVID-19 in some countries, it’s again pertinent to see if the same will aggravate health insurance penetration in India.

As we understand, pandemic in India brought about the much desired perception change on health insurance as a need based security to manage any unforeseen hospitalization which could otherwise wipe of savings and even push individuals towards a credit support to manage expenses. This will further be accelerated, said Amjad Khan, Director Employee Benefit practice and International business at Anand Rathi Insurance Brokers Pvt. Ltd.

“In the COVID times every alternate family in the country did go through a real life example of what hospitalisation could be with the financial impact they endured during these testing times. In the world of scare and greed, COVID-19 has managed to push the narrative towards a more prudent thinking in terms of preparing for bad times and hence the penetration will get the desired push for health insurance solutions,” Khan told CNBC-TV18.com.

People have now understood that they should always opt for policies that give higher coverage.

“Though consumers might have to pay more premium; they can be rest assured that they will receive better benefits compared to regular plans,” Indraneel Chatterjee, Co-Founder at RenewBuy said.

Will this increase premiums too?

Insurance premiums are likely to increase, experts say. The revisions can predominantly be linked with medical inflation (in health insurance category) and overall economic condition of the country.

According to a recent report by Indian financial services company Motilal Oswal Financial Services Limited, medical inflation in India has continued to rise. The report noted that room rents have increased 3-4 percent over the past one year.

The health insurance market, meanwhile, has expanded significantly since 2020, which presents an opportunity for the insurance industry. During the peak COVID-19 period (2021-22), premiums for health insurance in India had already increased by 25 percent compared to the pre-pandemic level.

“Insurers in India during the pandemic have settled more than 25,000 crore in hospitalisation claims and thus the impact on the underwriting margins got further stressed which anyways was in a bad shape. With medical inflation being at its peak, the hospitalisation costs have gone up compared to the pre covid era. This phenomena will definitely propel price correction and we will see premium hikes but with much wider and new coverages being introduced in the coming times,” Khan told CNBC-TV18.com.

ALSO READ | Consider discount on policy renewal for those with 3 doses of COVID-19 vaccine: Irdai to insurers

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

WHO backs face mask wearing on long flights as new Omicron variant spreads

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Passengers should be advised to wear masks in high-risk settings such as long-haul flights, said the WHO’s senior emergency officer for Europe, Catherine Smallwood, adding, “this should be a recommendation issued to passengers arriving from anywhere where there is widespread COVID-19 transmission”.

Countries should consider recommending passengers wear masks on long-haul flights to counter the latest Omicron subvariant of COVID-19 given its rapid spread in the United States, World Health Organization (WHO) officials said on Tuesday.

In Europe, the XBB.1.5 subvariant is being detected in small but growing numbers, WHO/Europe officials said at a press briefing.

Passengers should be advised to wear masks in high-risk settings such as long-haul flights, said the WHO’s senior emergency officer for Europe, Catherine Smallwood, adding, “this should be a recommendation issued to passengers arriving from anywhere where there is widespread COVID-19 transmission”.

XBB.1.5 — the most transmissible Omicron subvariant that has been detected so far — accounted for 27.6 percent of COVID-19 cases in the United States for the week ending January 7, US health officials said.

It remains unclear if XBB.1.5 will cause its own wave of infections around the world. Current vaccines continue to protect against severe symptoms, hospitalisation and death, experts say.

“Countries need to look at the evidence base for pre-departure testing”, Smallwood added, saying it was crucial not to focus exclusively on one particular geographic area.

If action is considered, she said, “our opinion is that travel measures should be implemented in a non-discriminatory manner”.

That did not mean the agency recommended testing for passengers coming from the United States at this stage, she added.

Measures that can be taken include genomic surveillance, and targeting passengers arriving from other countries as long as it does not divert resources away from domestic surveillance systems. Others include wastewater monitoring systems around points of entry, such as airports.

XBB.1.5 is yet another descendant of Omicron, the most contagious – and now globally dominant — variant of the virus that causes COVID-19. It is an offshoot of XBB, first detected in October, which is itself a recombinant of two other Omicron subvariants.

Also Read: Explained | Has Kashmir Files really been shortlisted for the Oscars?

Concerns about XBB.1.5 fuelling a fresh spate of cases in the United States and beyond are on the rise at the same time as a surge of COVID cases in China, after the country pivoted away from its signature “zero COVID” policy last month.

According to data reported by the WHO earlier this month, an analysis by the Chinese Center for Disease Control and Prevention showed a predominance of Omicron sublineages BA.5.2 and BF.7 among locally acquired infections.

Many scientists – including from the WHO — believe China is likely under-reporting the true extent of its outbreak.

More than a dozen countries — including the United States — are demanding COVID tests from travellers from China.

Also Read: Saudi Arabia removes restrictions on Hajj pilgrim numbers; check details

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Omicron sub-variant XBB.1.5 explained — transmissibility, severity, immune evasive effects and more

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Now that seven cases of Omicron sub-variant XBB.1.5 have been reported in India, how worried should the country be — in terms of the surge in cases, deaths, hospitalisations, vaccination and severity? Read on to know.

India has so far reported seven XBB.1.5 variant cases, according to the data released by the Indian SARS-CoV-2 Genomics Consortium (INSACOG) on Thursday. As per the information, these seven were identified in Gujarat, Karnataka, Telangana, Chhattisgarh and Rajasthan.

This XBB.1.5 Omicron is dominant in the United States (ST) and is said to be responsible for the rise in cases there. Combined, XBB and XBB.1.5 make up 44 percent of cases in the US as of now, PTI reports.

ALSO READ | A factcheck on COVID-19 symptoms — Does muscle pain, dry mouth, skipping meals indicate infection

The World Health Organization (WHO) recently highlighted that this XBB.1.5 variant is the “most transmissible sub-variant that has been recorded yet”, said WHO epidemiologist Maria Van Kerkhove.

ALSO READ | COVID-19: India detects 11 new Omicron sub-variants in international travellers

Now that seven cases of this variant have been reported in India, how worried should the country be — in terms of the surge in cases, deaths, hospitalisations, vaccination and severity?

Will India see a surge in COVID-19 cases triggered by the most contagious XBB1.5 variant?

Virologist Gagandeep Kang says she does not expect a surge in India, noting that “XBB and BF.7 for a while and they have not driven an upsurge in India. In the absence of an even more highly infectious variant, I do not expect a surge.”

She mentions “hybrid” immunity among Indians as another reason to rule out the surge. Hybrid immunity is achieved by a person if he or she had been infected with the virus and has also been vaccinated.

Will there be a spike in deaths among those infected with XBB.1.5 COVID variant?

While WHO expects “further waves of infections around the world”, Kerkhove says “it does not have to necessarily translate into further waves of death.”

Can XBB.1.5 COVID variant escape immunity?

Yes, it can, as noted by WHO’s Kerkhove. She said, “It (XBB.1.5) is replacing other sub-variants in some countries and has “immune escape like XBB”.

Are vaccines effective against XBB.1.5 Omicron variant?

There are chances that people with prior infection or even those vaccinated against the coronavirus can get infected with XBB.1.5 Omicron variant.

“Immune evasiveness is the ability of the virus to infect people who had prior infection or vaccination or both. XBB.1.5 achieved this by creating a rare type of mutation…,” Dr Rajeev Jayadevan, Co-chairman of the National IMA Covid task force, was quoted by ANI as saying.

ALSO READ | Who can’t receive COVID-19 nasal vaccine — From benefits to side effects, here’s your one-stop guide

Moreover, according to a CNBC report, scientists said that XBB.1.5 is as good as XBB and XBB.1 at dodging antibodies from vaccines and infection.

But, current vaccines continue to protect against severe symptoms, hospitalisation and death, Reuters quoted experts as saying.

Does India need a fourth dose of COVID-19 vaccine?

Dr Chandrakant Lahariya, a leading public health and policy expert, don’t believe that a “healthy adult need a booster dose”. He had earlier told CNBCTV-18.com : “There’s a global evidence that while the third shot provides some benefit, the fourth shot has marginal benefits.”

Meanwhile, Kang said in a tweet posted on December 23, “Two doses of any vaccine protect against severe disease/deaths.” She further noted that “…from the rest of the world, the value of a booster in the elderly population is clear”.

Does XBB.1.5 variant cause more severe disease than other Omicron variants?

Experts believe it is unlikely to do so. The WHO epidemiologist said the world health body does not have any data on the severity of the variant so far. But “we don’t have any indication that the severity has changed”, she added. But, increased transmissibility is always a concern.

Will hospitalisations increase if XBB.1.5 variant becomes dominant?

The WHO was unable to attribute the increase in hospitalisations in the northeastern US to the variant. However, a month back, American epidemiologist Eric Feigl-Ding had warned that “super variant” XBB.1.5 is behind “hospitalisation surges in New York/New England”.

What is XBB.1.5 variant, where it originated and in how many countries it is present?

The XBB.1.5 strain is a relative of the Omicron XBB variant — which is a recombinant of the Omicron BA.2.10.1 and BA.2.75 subvariants.

The WHO says, “One of the Omicron sub-variants originally detected in October 2022 is XBB.1.5. It is on the increase in the US and Europe and has now been identified in more than 25 countries”.

COVID variant, driving surge in China, present in India

The INSACOG data also showed that seven cases of BF.7 strain, which is driving China’s COVID-19 wave, have been found in India. There are four cases of Omicron sub-variant BF.7 reported in West Bengal, two in Gujarat and one in Odisha.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?